Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 1
2004 1
2006 4
2007 1
2008 6
2009 7
2010 10
2011 7
2012 13
2013 13
2014 6
2015 8
2016 19
2017 20
2018 22
2019 35
2020 21
2021 11
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Results by year

Filters applied: . Clear all
Page 1
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Treatment of Posttransplantation Anemia.
Unagami K, Okumi M, Tamura T, Ishida H, Tanabe K, Nitta K. Unagami K, et al. Among authors: okumi m. Contrib Nephrol. 2018;195:92-101. doi: 10.1159/000486939. Epub 2018 May 7. Contrib Nephrol. 2018. PMID: 29734154 Review.
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review.
Tsuchimoto A, Masutani K, Omoto K, Okumi M, Okabe Y, Nishiki T, Ota M, Nakano T, Tsuruya K, Kitazono T, Nakamura M, Ishida H, Tanabe K; Japan Academic Consortium of Kidney Transplantation (JACK) Investigators. Tsuchimoto A, et al. Among authors: okumi m. Clin Exp Nephrol. 2019 Apr;23(4):561-568. doi: 10.1007/s10157-018-1672-1. Epub 2018 Dec 24. Clin Exp Nephrol. 2019. PMID: 30584654 Review.
Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry.
Fujiyama N, Tasaki M, Harada H, Tsutahara K, Matsumoto A, Kamijo Y, Toyoda M, Iwami D, Inui M, Shirakawa H, Sugimura J, Saito M, Hotta K, Okumi M, Saito K, Watarai Y, Hidaka Y, Ohtani K, Inoue N, Wakamiya N, Habuchi T, Satoh S; Japanese Post-kidney Transplant TMA Support Team. Fujiyama N, et al. Among authors: okumi m. Clin Exp Nephrol. 2023 Dec;27(12):1010-1020. doi: 10.1007/s10157-023-02391-5. Epub 2023 Aug 27. Clin Exp Nephrol. 2023. PMID: 37634218
188 results